These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 33504716)
1. Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Fukuda N; Toda K; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S Endocr J; 2021 Jun; 68(6):639-647. PubMed ID: 33504716 [TBL] [Abstract][Full Text] [Related]
2. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259 [TBL] [Abstract][Full Text] [Related]
3. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649 [TBL] [Abstract][Full Text] [Related]
4. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627 [TBL] [Abstract][Full Text] [Related]
5. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020 [No Abstract] [Full Text] [Related]
6. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. Brose MS; Worden FP; Newbold KL; Guo M; Hurria A J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956 [TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092 [TBL] [Abstract][Full Text] [Related]
8. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732 [No Abstract] [Full Text] [Related]
9. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967 [TBL] [Abstract][Full Text] [Related]
10. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life. Marotta V; Rocco D; Crocco A; Deiana MG; Martinelli R; Di Gennaro F; Valeriani M; Valvano L; Caleo A; Pezzullo L; Faggiano A; Vitale M; Monti S J Clin Endocrinol Metab; 2024 Sep; 109(10):2541-2552. PubMed ID: 38501238 [TBL] [Abstract][Full Text] [Related]
11. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Zheng X; Xu Z; Ji Q; Ge M; Shi F; Qin J; Wang F; Chen G; Zhang Y; Huang R; Tan J; Huang T; Li S; Lv Z; Lin Y; Guo Z; Kubota T; Suzuki T; Ikezawa H; Gao M Clin Cancer Res; 2021 Oct; 27(20):5502-5509. PubMed ID: 34326132 [TBL] [Abstract][Full Text] [Related]
12. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea. Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091 [No Abstract] [Full Text] [Related]
13. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Otsuki N; Nibu KI; Minami H Head Neck; 2019 Sep; 41(9):3023-3032. PubMed ID: 31013380 [TBL] [Abstract][Full Text] [Related]
14. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib. Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774 [TBL] [Abstract][Full Text] [Related]
15. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104 [TBL] [Abstract][Full Text] [Related]
16. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178 [TBL] [Abstract][Full Text] [Related]
17. Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Fukuda N; Toda K; Ohmoto A; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S Anticancer Res; 2021 Mar; 41(3):1683-1691. PubMed ID: 33788766 [TBL] [Abstract][Full Text] [Related]
18. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739 [No Abstract] [Full Text] [Related]
19. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689 [TBL] [Abstract][Full Text] [Related]
20. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States. Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]